WHO Emergency Use Listing for AstraZeneca/Oxford COVID-19 Vaccine

The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organization (WHO), as co-leads of the COVAX initiative for equitable global access to COVID-19 vaccines, alongside key delivery partner UNICEF, are pleased to welcome the news that two versions of the AstraZeneca/Oxford COVID-19 vaccine have been given WHO Emergency Use Listing (EUL). Yesterday’s announcement means that two versions of the AstraZeneca/Oxford vaccine, produced by AstraZeneca-SK Bioscience (AZ-SKBio) and the Serum Institute of India (AZ-SII), are now available for global rollout through the COVAX Facility.

Building on the early information provided in the interim distribution forecast published on 3 February 2021, COVAX will now complete the process of final Q1/Q2 allocations of the AstraZeneca/Oxford vaccine to Facility participants. Information on these final allocations will be communicated to all participants and published online the week of February 22nd.

Detailed information about the Astra Zeneca/Oxford COVID-19 Vaccine go oh the official site of WHO news item.

https://www.who.int/news/item/16-02-2021-covax-statement-on-who-emergency-use-listing-for-astrazeneca-oxford-covid-19-vaccine

                                                                                                             

Leave a Reply

Your email address will not be published. Required fields are marked *